Metastatic Pancreatic Ductal Adenocarcinoma clinical trials

Explore recruiting metastatic pancreatic ductal adenocarcinoma clinical trials.

Recruiting metastatic pancreatic ductal adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Pancreatic Ductal Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy

Spain, Italy, Netherlands, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously I) with first-line standard of care nab-paclitaxel and gemcitabine, or II) in combination with MEK inhibitor maintenance therapy

Germany, Spain, Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

“NALPAC” A NON-COMPARATIVE RANDOMIZED PHASE 2 STUDY, EVALUATING THE EFFICACY OF 5-FU + NALIRI AND 5-FU + NALIRINOX FOR METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC), PROGRESSIVE AFTER GEMCITABINE-ABRAXANE OR GEMCITABINE MONOTHERAPY.

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma

France, Belgium, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Italy, Germany, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer

Spain, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Metastatic Pancreatic Ductal Adenocarcinoma trials by city

Metastatic Pancreatic Ductal Adenocarcinoma in Toronto Metastatic Pancreatic Ductal Adenocarcinoma in Vancouver Metastatic Pancreatic Ductal Adenocarcinoma in Montreal Metastatic Pancreatic Ductal Adenocarcinoma in Calgary Metastatic Pancreatic Ductal Adenocarcinoma in Edmonton Metastatic Pancreatic Ductal Adenocarcinoma in Ottawa Metastatic Pancreatic Ductal Adenocarcinoma in Winnipeg Metastatic Pancreatic Ductal Adenocarcinoma in Quebec City Metastatic Pancreatic Ductal Adenocarcinoma in Hamilton Metastatic Pancreatic Ductal Adenocarcinoma in Kitchener Metastatic Pancreatic Ductal Adenocarcinoma in London Metastatic Pancreatic Ductal Adenocarcinoma in Halifax Metastatic Pancreatic Ductal Adenocarcinoma in New York Metastatic Pancreatic Ductal Adenocarcinoma in Los Angeles Metastatic Pancreatic Ductal Adenocarcinoma in Chicago Metastatic Pancreatic Ductal Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease